Asylia Diagnostics

A diagnostics technology platform for immuno-oncology

Date of establishment: 2016-08-22
Active in: HealthTech

We empower cancer patients, medical oncologists, and drug development companies to have an informed decision about the safety of immunotherapy by providing reliable companion diagnostics technology platform. Our first product - already in clinical studies in Belgium - is targeting hyperprogressive disease, a severe adverse effect of immune checkpoint blockade affecting 5-29% of patients. 

Share this on


This website uses cookies for analytics purposes only without any commercial intent. Find out more here. Our privacy statement can be found here. Some content (videos, iframes, forms,...) on this website will only appear when you have accepted the cookies.

Accept cookies